Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence summary HPA evidence UniProt evidence MS evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location RNA tissue category RNA TS RNA TS FPKM FPKM max in non-specific AVPR1B AVPR3 ENSG00000198049 Arginine vasopressin receptor 1B 1 206109692-206117699 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at transcript level No evidence Evidence at transcript level HPA017337 Uncertain Not detected stomach: 0.2 AVPR2 DIR, DIR3, V2R ENSG00000126895 Arginine vasopressin receptor 2 X 153902531-153907166 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level Evidence at transcript level Evidence at protein level HPA046678 Uncertain Mixed adipose tissue: 3.4 C3 ARMD9, C3a, C3b, CPAMD1 ENSG00000125730 Complement component 3 19 6677704-6730562 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA003563, CAB004209, HPA020432 Supportive Tissue enriched 6 liver: 2172.5 adipose tissue: 386.5 C4A C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG ENSG00000244731 Complement component 4A (Rodgers blood group) 6 31982024-32002681 Blood group antigen proteins, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Evidence at transcript level Evidence at protein level Evidence at protein level CAB009811, CAB032603, HPA046356, HPA048287, HPA050103 Uncertain Tissue enhanced 0 liver: 152.4 adrenal gland: 32.9 C4B C4B1, C4B3, C4F, CH, CO4, CPAMD3 ENSG00000224389 Complement component 4B (Chido blood group) 6 32014762-32035418 Blood group antigen proteins, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Evidence at transcript level Evidence at protein level Evidence at protein level HPA046356, HPA048287, HPA050103 Uncertain Tissue enhanced 0 liver: 168.2 adrenal gland: 38.2 C5 C5a, C5b, CPAMD4 ENSG00000106804 Complement component 5 9 120952335-121050276 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Evidence at transcript level Evidence at protein level Evidence at protein level HPA029339 Uncertain Tissue enriched 22 liver: 141.5 lung: 6.5 CD2 SRBC ENSG00000116824 CD2 molecule 1 116754385-116769228 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB002430, HPA003883 Supportive Supportive Nucleus but not nucleoli, Nucleoli Tissue enhanced 0 lymph node: 94.5 tonsil: 60.6 CD247 CD3H, CD3Q, CD3Z ENSG00000198821 CD247 molecule 1 167430640-167518610 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB004651, HPA008750 Supportive Tissue enhanced 0 lymph node: 51.5 tonsil: 32.6 CD33 FLJ00391, p67, SIGLEC-3, SIGLEC3 ENSG00000105383 CD33 molecule 19 51225064-51243860 CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB011442, HPA035832, HPA064807 Uncertain Supportive Nucleus, Plasma membrane Mixed spleen: 20.1 CD3D T3D ENSG00000167286 CD3d molecule, delta (CD3-TCR complex) 11 118338954-118342744 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB013055 Supportive Tissue enhanced 0 lymph node: 130.9;tonsil: 95.8 appendix: 53.3 CD3E ENSG00000198851 CD3e molecule, epsilon (CD3-TCR complex) 11 118304545-118316175 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB000010, HPA040957, HPA043955, CAB072863, CAB072864 Supportive Tissue enhanced 0 lymph node: 162.1;tonsil: 109.6 appendix: 65.7 CD3G ENSG00000160654 CD3g molecule, gamma (CD3-TCR complex) 11 118344344-118355161 CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB017520, HPA038494 Supportive Tissue enhanced 0 lymph node: 28.9;tonsil: 21.5 appendix: 11.7 CD4 ENSG00000010610 CD4 molecule 12 6786858-6820808 CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB000011, HPA004252, HPA004472, CAB068180 Supportive Supportive Plasma membrane Expressed in all spleen: 132.3 CD80 B7-1, B7.1, CD28LG, CD28LG1 ENSG00000121594 CD80 molecule 3 119524293-119559602 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level CAB025368, HPA050092 Supportive Tissue enhanced 0 appendix: 4.1;lymph node: 4.5;tonsil: 5.0 spleen: 2.1 CD86 B7-2, B7.2, CD28LG2 ENSG00000114013 CD86 molecule 3 122055366-122121139 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB004319 Uncertain Mixed appendix: 31.6 CSF2RA CD116, CSF2R ENSG00000198223 Colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) X 1268800-1310381 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at transcript level Evidence at protein level Evidence at protein level CAB016148 Uncertain Tissue enhanced 0 placenta: 59.8 appendix: 21.6 CSF2RB CD131, IL3RB, IL5RB ENSG00000100368 Colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) 22 36913628-36940449 CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB010251 Uncertain Tissue enhanced 0 appendix: 56.5;tonsil: 51.6 lymph node: 32.5 CSF3R CD114, GCSFR ENSG00000119535 Colony stimulating factor 3 receptor (granulocyte) 1 36466043-36483278 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level CAB017116, HPA048086 Supportive Tissue enhanced 0 appendix: 129.5;bone marrow: 209.9;placenta: 107.7 spleen: 65.5 EGFR ERBB, ERBB1 ENSG00000146648 Epidermal growth factor receptor 7 55019021-55256620 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB000035, HPA001200, HPA018530, CAB068186, CAB073534 Supportive Supportive Plasma membrane Tissue enhanced 0 placenta: 61.3 skin: 35.8 ELANE ELA2, HLE, HNE, NE ENSG00000197561 Elastase, neutrophil expressed 19 851014-856247 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB015409 Supportive Tissue enriched 471 bone marrow: 1925.8 skin: 4.0 ERBB2 CD340, HER-2, HER2, NEU, NGL ENSG00000141736 V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 17 39687914-39730426 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB000043, HPA001338, HPA001383, CAB020416, CAB062555 Uncertain Supportive Nucleus, Plasma membrane, Cytoplasm Expressed in all esophagus: 69.5 F2 ENSG00000180210 Coagulation factor II (thrombin) 11 46719180-46739506 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB016780, CAB018650, HPA051476, HPA054698 Supportive Tissue enriched 2559 liver: 514.8 gallbladder: 0.2 F5 ENSG00000198734 Coagulation factor V (proaccelerin, labile factor) 1 169514166-169586588 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Evidence at transcript level Evidence at protein level Evidence at protein level HPA002036 Uncertain Uncertain Golgi apparatus Group enriched 10 gallbladder: 17.9;liver: 71.7;placenta: 40.0 stomach: 4.2 F8 DXS1253E, F8C, FVIII, HEMA ENSG00000185010 Coagulation factor VIII, procoagulant component X 154835788-155026940 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB018777 Supportive Expressed in all adipose tissue: 15.0 FCER1A FCE1A ENSG00000179639 Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide 1 159289714-159308224 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level CAB022102 Supportive Mixed skin: 22.8 FCGR2A CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1, IGFR2 ENSG00000143226 Fc fragment of IgG, low affinity IIa, receptor (CD32) 1 161505430-161524013 CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA010718, HPA014730 Supportive Mixed appendix: 80.9 FCGR2B CD32, CD32B, FCG2, FCGR2 ENSG00000072694 Fc fragment of IgG, low affinity IIb, receptor (CD32) 1 161581311-161678654 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB007796, HPA014730 Supportive Tissue enriched 8 placenta: 170.4 tonsil: 20.1 FCGR3A CD16, CD16a, FCG3, FCGR3 ENSG00000203747 Fc fragment of IgG, low affinity IIIa, receptor (CD16a) 1 161541759-161550737 CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB032435, HPA055431 Supportive Expressed in all spleen: 203.8 FGA ENSG00000171560 Fibrinogen alpha chain 4 154583126-154590766 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB016776, HPA051370, HPA064755 Supportive Tissue enriched 273 liver: 5995.6 stomach: 21.9 FGFR2 BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25 ENSG00000066468 Fibroblast growth factor receptor 2 10 121478334-121598458 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB010886, HPA035305, HPA056562 Uncertain Supportive Vesicles, Cell Junctions, Nucleus Mixed skin: 56.0 FN1 CIG, FINC, GFND2, LETS, MSF ENSG00000115414 Fibronectin 1 2 215360440-215436172 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB000126, HPA027066 Supportive Tissue enhanced 0 placenta: 2101.5 liver: 721.6 FOLH1 FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA ENSG00000086205 Folate hydrolase (prostate-specific membrane antigen) 1 11 49146635-49208670 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB001451, HPA010593 Supportive Tissue enhanced 0 duodenum: 203.1;prostate: 83.3 small intestine: 60.1 GLP2R ENSG00000065325 Glucagon-like peptide 2 receptor 17 9822206-9892102 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level HPA049244 Supportive Tissue enhanced 0 gallbladder: 11.2 duodenum: 7.7 IFNAR1 IFNAR, IFRC ENSG00000142166 Interferon (alpha, beta and omega) receptor 1 21 33324477-33359862 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA018015, HPA029226 Uncertain Uncertain Cytoplasm Expressed in all thyroid gland: 24.6 IFNAR2 IFNABR ENSG00000159110 Interferon (alpha, beta and omega) receptor 2 21 33229901-33265675 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at transcript level Evidence at protein level Evidence at protein level CAB025889 Uncertain Expressed in all appendix: 33.1 IFNGR1 CD119, IFNGR ENSG00000027697 Interferon gamma receptor 1 6 137197484-137219449 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at transcript level Evidence at protein level Evidence at protein level CAB004444, HPA029213, HPA063871 Uncertain Uncertain Vesicles, Cytoplasm Expressed in all spleen: 130.8 IFNGR2 AF-1, IFNGT1 ENSG00000159128 Interferon gamma receptor 2 (interferon gamma transducer 1) 21 33402896-33479348 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Evidence at transcript level Evidence at protein level HPA001535 Uncertain Uncertain Nucleus but not nucleoli, Golgi apparatus Expressed in all placenta: 74.3 IGF1R CD221, IGFIR, IGFR, JTK13, MGC18216 ENSG00000140443 Insulin-like growth factor 1 receptor 15 98648971-98964530 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level Evidence at transcript level Evidence at protein level Evidence at protein level CAB010268, HPA045563 Uncertain Uncertain Vesicles Expressed in all fallopian tube: 15.3 IL11RA ENSG00000137070 Interleukin 11 receptor, alpha 9 34650702-34661892 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level HPA013162, CAB032830, HPA036652 Uncertain Expressed in all skin: 32.3 IL17A CTLA8, IL-17, IL-17A, IL17 ENSG00000112115 Interleukin 17A 6 52186387-52190638 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Evidence at transcript level Evidence at protein level HPA052258 Uncertain Group enriched 5 appendix: 0.7;tonsil: 1.1;urinary bladder: 1.2 gallbladder: 0.2 IL1R1 CD121A, D2S1473, IL1R, IL1RA ENSG00000115594 Interleukin 1 receptor, type I 2 102064544-102179874 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA005823, CAB007779, HPA029560 Uncertain Expressed in all gallbladder: 89.2 IL2RA CD25, IDDM10, IL2R ENSG00000134460 Interleukin 2 receptor, alpha 10 6010689-6062325 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB002419, HPA054622 Supportive Tissue enhanced 0 adipose tissue: 14.8;lymph node: 15.2 appendix: 12.0 IL2RB CD122, IL15RB ENSG00000100385 Interleukin 2 receptor, beta 22 37125838-37175054 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA051627, HPA062657 Supportive Uncertain Nucleus, Nucleoli Tissue enhanced 0 spleen: 45.6 lymph node: 29.2 IL2RG CD132, CIDX, IMD4, SCIDX1 ENSG00000147168 Interleukin 2 receptor, gamma X 71107404-71112108 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA046641 Supportive Tissue enhanced 0 lymph node: 219.7;tonsil: 264.8 appendix: 125.4 IL3RA CD123 ENSG00000185291 Interleukin 3 receptor, alpha (low affinity) X 1336616-1382689 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA003539, CAB018374 Uncertain Expressed in all lymph node: 14.1 INSR CD220 ENSG00000171105 Insulin receptor 19 7112255-7294034 CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA036302, HPA036303 Uncertain Supportive Vesicles Expressed in all ovary: 24.6 ITGA2B CD41, CD41B, GP2B, PPP1R93 ENSG00000005961 Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) 17 44372180-44389505 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB018611, HPA031168, HPA031169, HPA031170, HPA031171 Supportive Supportive Nucleus but not nucleoli, Cytoplasm Tissue enhanced 0 bone marrow: 9.0 thyroid gland: 2.5 ITGAL CD11A, LFA-1 ENSG00000005844 Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) 16 30472658-30523185 CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB025011 Supportive Tissue enhanced 0 lymph node: 57.8;spleen: 51.6 tonsil: 41.3 ITGAV CD51, MSK8, VNRA, VTNR ENSG00000138448 Integrin, alpha V 2 186590065-186680901 Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB002499, HPA004856 Supportive Uncertain Cytoplasm, Focal Adhesions Expressed in all thyroid gland: 59.5 ITGB1 CD29, FNRB, GPIIA, MDF2, MSK12 ENSG00000150093 Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) 10 32900319-33005792 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB003434 Uncertain Supportive Plasma membrane, Focal Adhesions, Endoplasmic reticulum Expressed in all smooth muscle: 448.9 ITGB3 CD61, GP3A, GPIIIa ENSG00000259207 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 17 47253846-47311816 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA027852 Supportive Tissue enhanced 0 thyroid gland: 44.4 smooth muscle: 19.9 LHCGR HHG, LCGR, LGR2, LHR, ULG5 ENSG00000138039 Luteinizing hormone/choriogonadotropin receptor 2 48686775-48755730 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB009814 Uncertain Tissue enhanced 0 testis: 2.4 ovary: 1.0 M6PR ENSG00000003056 Mannose-6-phosphate receptor (cation dependent) 12 8940363-8949955 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB034464, HPA040445 Uncertain Expressed in all lymph node: 88.2 MPL CD110, TPOR ENSG00000117400 MPL proto-oncogene, thrombopoietin receptor 1 43337807-43352772 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB002011, HPA007619 Supportive Plasma membrane Not detected ovary: 0.4 MS4A1 B1, Bp35, CD20, MS4A2 ENSG00000156738 Membrane-spanning 4-domains, subfamily A, member 1 11 60455752-60470760 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB000015, HPA014341, HPA014391 Supportive Group enriched 13 appendix: 176.9;lymph node: 562.2;spleen: 290.3;tonsil: 731.0 urinary bladder: 33.2 MS4A2 APY, FCER1B, IGER, MS4A1 ENSG00000149534 Membrane-spanning 4-domains, subfamily A, member 2 11 60088261-60098466 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at transcript level HPA059967 Supportive Mixed lung: 15.6 OXTR ENSG00000180914 Oxytocin receptor 3 8750408-8769628 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at transcript level Evidence at protein level Evidence at protein level CAB022700 Uncertain Tissue enhanced 0 fallopian tube: 3.1;ovary: 2.4 endometrium: 1.5 PDGFRB CD140b, JTK12, PDGFR, PDGFR1 ENSG00000113721 Platelet-derived growth factor receptor, beta polypeptide 5 150113837-150155872 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB003842, CAB018144, HPA028499 Supportive Uncertain Cytoplasm, Vesicles Mixed gallbladder: 125.2 PGF D12S1900, PGFL, PLGF, PlGF-2, SHGC-10760 ENSG00000119630 Placental growth factor 14 74941834-74955784 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level Evidence at transcript level Evidence at protein level HPA041624 Uncertain Nucleus but not nucleoli, Cytoplasm, Mitochondria Tissue enhanced 0 placenta: 56.4;thyroid gland: 37.1 fallopian tube: 12.6 PLAT ENSG00000104368 Plasminogen activator, tissue 8 42175233-42207724 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA003412, CAB009335 Supportive Uncertain Cytoskeleton (Actin filaments) Mixed urinary bladder: 114.6 PLAU UPA, URK ENSG00000122861 Plasminogen activator, urokinase 10 73909177-73917497 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Evidence at transcript level Evidence at protein level Evidence at protein level HPA008719 Uncertain Uncertain Plasma membrane, Cytoplasm Expressed in all urinary bladder: 42.0 PLAUR CD87, UPAR, URKR ENSG00000011422 Plasminogen activator, urokinase receptor 19 43646095-43670547 Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA050843, CAB073533 Uncertain Supportive Plasma membrane Tissue enhanced 0 bone marrow: 379.5 gallbladder: 77.2 PLG ENSG00000122194 Plasminogen 6 160702238-160753315 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB000668, CAB016678, HPA021602, HPA048823 Supportive Tissue enriched 6 liver: 1009.2 kidney: 171.4 PLIN3 M6PRBP1, PP17, TIP47 ENSG00000105355 Perilipin 3 19 4838341-4867768 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA006427, HPA066538 Uncertain Supportive Vesicles Expressed in all esophagus: 82.5 PTH2R PTHR2 ENSG00000144407 Parathyroid hormone 2 receptor 2 208359714-208854503 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Evidence at transcript level Evidence at protein level HPA010655 Uncertain Tissue enhanced 0 bone marrow: 2.0 salivary gland: 1.5 RAMP1 ENSG00000132329 Receptor (G protein-coupled) activity modifying protein 1 2 237858893-237912114 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Evidence at transcript level Evidence at protein level Evidence at protein level HPA057814 Uncertain Nucleus but not nucleoli, Nuclear membrane Mixed endometrium: 114.8 SCTR ENSG00000080293 Secretin receptor 2 119439843-119524494 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level Evidence at protein level Evidence at transcript level HPA007269 Uncertain Group enriched 5 duodenum: 15.6;lung: 4.6;pancreas: 11.6 kidney: 2.1 SERPINB2 HsT1201, PAI2, PLANH2 ENSG00000197632 Serpin peptidase inhibitor, clade B (ovalbumin), member 2 18 63871692-63903890 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA015480 Supportive Tissue enhanced 0 esophagus: 195.4;skin: 62.6;tonsil: 68.0 placenta: 37.0 SERPINC1 AT3, ATIII, MGC22579 ENSG00000117601 Serpin peptidase inhibitor, clade C (antithrombin), member 1 1 173903804-173917378 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA001816, CAB016790, HPA024007 Supportive Tissue enriched 933 liver: 1398.1 kidney: 1.4 SERPIND1 D22S673, HC-II, HC2, HCF2, HLS2 ENSG00000099937 Serpin peptidase inhibitor, clade D (heparin cofactor), member 1 22 20773879-20787720 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB008639, HPA055767 Supportive Tissue enriched 191 liver: 389.7 placenta: 2.0 SERPINE1 PAI, PAI1, PLANH1 ENSG00000106366 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 7 101127089-101139266 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Evidence at transcript level Evidence at protein level Evidence at protein level HPA050039 Uncertain Uncertain Cytoplasm Tissue enhanced 0 gallbladder: 334.5;placenta: 276.1 liver: 199.2 SNAP25 bA416N4.2, dJ1068F16.2, RIC-4, RIC4, SEC9, SNAP, SNAP-25 ENSG00000132639 Synaptosomal-associated protein, 25kDa 20 10218830-10307418 FDA approved drug targets, Predicted intracellular proteins, Transporters Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB000360, HPA001830 Supportive Uncertain Cytoplasm, Golgi apparatus, Cytoskeleton (Actin filaments), Nucleus, Nucleoli Tissue enriched 23 cerebral cortex: 916.5 adrenal gland: 39.9 SYT2 ENSG00000143858 Synaptotagmin II 1 202590596-202710417 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level HPA030372, HPA063655 Supportive Supportive Vesicles Tissue enhanced 0 adrenal gland: 1.4;cerebral cortex: 1.1 testis: 0.6 TNFRSF8 CD30, D1S166E, KI-1 ENSG00000120949 Tumor necrosis factor receptor superfamily, member 8 1 12063377-12144207 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB000016, HPA032081, HPA032082 Supportive Mixed appendix: 2.0 TNFSF11 CD254, ODF, OPGL, RANKL, TRANCE ENSG00000120659 Tumor necrosis factor (ligand) superfamily, member 11 13 42562736-42608013 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level CAB009193, HPA045142 Supportive Tissue enhanced 0 lymph node: 13.2 appendix: 4.6 TNFSF13B BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20 ENSG00000102524 Tumor necrosis factor (ligand) superfamily, member 13b 13 108251240-108308484 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB009188 Uncertain Mixed appendix: 25.7 TSHR LGR3 ENSG00000165409 Thyroid stimulating hormone receptor 14 80954989-81146302 Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Evidence at transcript level Evidence at protein level CAB000473, HPA026680 Uncertain Tissue enriched 194 thyroid gland: 223.2 lymph node: 1.1 VAMP1 SYB1, VAMP-1 ENSG00000139190 Vesicle-associated membrane protein 1 (synaptobrevin 1) 12 6462237-6470987 FDA approved drug targets, Mitochondrial proteins, Predicted membrane proteins, Transporters Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB002779, CAB016119 Uncertain Expressed in all bone marrow: 34.5 VEGFA VEGF, VEGF-A, VPF ENSG00000112715 Vascular endothelial growth factor A 6 43770184-43786487 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB005429, CAB039240 Supportive Supportive Mitochondria Expressed in all thyroid gland: 285.9 VEGFB VEGFL, VRF ENSG00000173511 Vascular endothelial growth factor B 11 64234538-64238793 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level Evidence at transcript level Evidence at protein level Evidence at protein level CAB025499 Uncertain Expressed in all adipose tissue: 121.4 VWF F8VWF ENSG00000110799 Von Willebrand factor 12 5948874-6124770 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Evidence at protein level Evidence at protein level Evidence at protein level CAB001694, HPA001815, HPA002082, CAB072874, CAB072875 Supportive Mixed adipose tissue: 100.9